Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00429949 · OUTCOME

Duration of Response

A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma · Source last updated 2014-08-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
cycles
Interval / dispersion
Not reported
Time frame
Completion of treatment (median duration of therapy was 51 days)

What was measured

Duration of response is measured from the first date that criteria are met for complete response or partial response until the first date that criteria for relapse or progressive disease are met.

Analysis population: Only one patient achieved a partial response.

Groups in this outcome

Dasatinib

Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle. In patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dasatinib1

Reported measurements

Source class 1
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dasatinib3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
Duration of response is measured from the first date that criteria are met for complete response or partial response until the first date that criteria for relapse or progressive disease are met.
groups
  1. description
    Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle. In patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle.
    id
    OG000
    title
    Dasatinib
param Type
NUMBER
population Description
Only one patient achieved a partial response.
reporting Status
POSTED
time Frame
Completion of treatment (median duration of therapy was 51 days)
title
Duration of Response
type
SECONDARY
unit Of Measure
cycles

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice